Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
    • Transkriptit
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Nora AI
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Lehdistötiedote

Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial

Lifecare

Bergen, Norway, 27 May 2025 – Lifecare ASA (LIFE), a medtech company developing next-generation Continuous Glucose Monitoring (CGM) technology, is pleased to announce that Professor Simon Nitter Dankel has been appointed as Principal Investigator for its upcoming clinical trial.

Prof. Dankel is a leading expert in metabolic diseases and nutritional biochemistry, with an impressive track record of high-impact research and leadership in clinical trials. He currently heads the Research Unit for Health Surveys (RUHS) at the University of Bergen, which will host the first trial site.

RUHS brings extensive experience in executing clinical and decentralized trials and offers state-of-the-art infrastructure including a metabolic kitchen, biobank collaboration, and GDPR-compliant digital systems for participant management. This partnership sets the stage for robust, high-quality data collection and world-class regulatory standards.

This appointment follows Lifecare’s recent filing for regulatory approval to launch the clinical trial of its innovative CGM implant, marking another key milestone toward CE-marking and commercial launch.

“Engaging Prof. Dankel and RUHS is a strategic move that highlights our commitment to scientific excellence and clinical rigor,” said Joacim Holter, CEO of Lifecare ASA. “Their expertise will be instrumental as we accelerate efforts to bring our transformative technology to people living with diabetes.”

About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Attachments
Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.